Skip to main content
Top
Published in: Journal of Neural Transmission 5/2020

Open Access 01-05-2020 | Neurology and Preclinical Neurological Studies - Original Article

Subacute administration of both methcathinone and manganese causes basal ganglia damage in mice resembling that in methcathinone abusers

Authors: Andres Asser, Atsuko Hikima, Mari Raki, Kim Bergström, Sarah Rose, Julius Juurmaa, Villem Krispin, Mari Muldmaa, Stella Lilles, Hanna Rätsep, Peter Jenner, Sulev Kõks, Pekka T. Männistö, Pille Taba

Published in: Journal of Neural Transmission | Issue 5/2020

Login to get access

Abstract

An irreversible extrapyramidal syndrome occurs in man after intravenous abuse of “homemade” methcathinone (ephedrone, Mcat) that is contaminated with manganese (Mn) and is accompanied by altered basal ganglia function. Both Mcat and Mn can cause alterations in nigrostriatal function but it remains unknown whether the effects of the ‘homemade’ drug seen in man are due to Mcat or to Mn or to a combination of both. To determine how toxicity occurs, we have investigated the effects of 4-week intraperitoneal administration of Mn (30 mg/kg t.i.d) and Mcat (100 mg/kg t.i.d.) given alone, on the nigrostriatal function in male C57BL6 mice. The effects were compared to those of the ‘homemade’ mixture which contained about 7 mg/kg of Mn and 100 mg/kg of Mcat. Motor function, nigral dopaminergic cell number and markers of pre- and postsynaptic dopaminergic neuronal integrity including SPECT analysis were assessed. All three treatments had similar effects on motor behavior and neuronal markers. All decreased motor activity and induced tyrosine hydroxylase positive cell loss in the substantia nigra. All reduced 123I-epidepride binding to D2 receptors in the striatum. Vesicular monoamine transporter 2 (VMAT2) binding was not altered by any drug treatment. However, Mcat treatment alone decreased levels of the dopamine transporter (DAT) and Mn alone reduced GAD immunoreactivity in the striatum. These data suggest that both Mcat and Mn alone could contribute to the neuronal damage caused by the ‘homemade’ mixture but that both produce additional changes that contribute to the extrapyramidal syndrome seen in man.
Literature
go back to reference Angoa-Perez M, Anneken JH, Kuhn DM (2017) Neurotoxicology of synthetic cathinone analogs. Curr Top Behav Neurosci 32:209–230CrossRef Angoa-Perez M, Anneken JH, Kuhn DM (2017) Neurotoxicology of synthetic cathinone analogs. Curr Top Behav Neurosci 32:209–230CrossRef
go back to reference Anneken JH, Angoa-Perez M, Sati GC, Crich D, Kuhn DM (2017) Dissecting the influence of two structural substituents on the differential neurotoxic effects of acute methamphetamine and mephedrone treatment on dopamine nerve endings with the use of 4-methylmethamphetamine and methcathinone. J Pharmacol Exp Ther 360:417–423CrossRef Anneken JH, Angoa-Perez M, Sati GC, Crich D, Kuhn DM (2017) Dissecting the influence of two structural substituents on the differential neurotoxic effects of acute methamphetamine and mephedrone treatment on dopamine nerve endings with the use of 4-methylmethamphetamine and methcathinone. J Pharmacol Exp Ther 360:417–423CrossRef
go back to reference Ares-Santos S, Granado N, Espadas I, Martinez-Murillo R, Moratalla R (2014) Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining. Neuropsychopharmacology 39:1066–1080CrossRef Ares-Santos S, Granado N, Espadas I, Martinez-Murillo R, Moratalla R (2014) Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining. Neuropsychopharmacology 39:1066–1080CrossRef
go back to reference Asser A, Kõks S, Snellman A, Haaparanta-Solin M, Arponen E, Grönroos T et al (2016) Increased striatal VMAT2 binding in mice after chronic administration of methcathinone and manganese. Brain Res 1652:97–102CrossRef Asser A, Kõks S, Snellman A, Haaparanta-Solin M, Arponen E, Grönroos T et al (2016) Increased striatal VMAT2 binding in mice after chronic administration of methcathinone and manganese. Brain Res 1652:97–102CrossRef
go back to reference Bukhatwa S, Iravani MM, Zeng BY, Cooper JD, Rose S, Jenner P (2009) An immunohistochemical and stereological analysis of PSI-induced nigral neuronal degeneration in the rat. J Neurochem 109:52–59CrossRef Bukhatwa S, Iravani MM, Zeng BY, Cooper JD, Rose S, Jenner P (2009) An immunohistochemical and stereological analysis of PSI-induced nigral neuronal degeneration in the rat. J Neurochem 109:52–59CrossRef
go back to reference Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulezer A, Sitte HH, Baumann MH (2013) Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur J Pharmacol 699:180–187CrossRef Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulezer A, Sitte HH, Baumann MH (2013) Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur J Pharmacol 699:180–187CrossRef
go back to reference Emerson TS, Cisek JE (1993) Methcathinone: a Russian designer amphetamine infiltrates the rural midwest. Ann Emerg Med 22:1897–1903CrossRef Emerson TS, Cisek JE (1993) Methcathinone: a Russian designer amphetamine infiltrates the rural midwest. Ann Emerg Med 22:1897–1903CrossRef
go back to reference Guilarte T (2013) Manganese neurotoxicity: new perspectives from behavioural, neuroimaging, and neuropathological studies in humans and non-human primates. Front Aging Neurosci 2013(5):23 Guilarte T (2013) Manganese neurotoxicity: new perspectives from behavioural, neuroimaging, and neuropathological studies in humans and non-human primates. Front Aging Neurosci 2013(5):23
go back to reference Iravani MM, Kashefi K, Mander S, Rose S, Jenner P (2002) Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110(1):49–58CrossRef Iravani MM, Kashefi K, Mander S, Rose S, Jenner P (2002) Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110(1):49–58CrossRef
go back to reference Iravani MM, Leung CCM, Sadeghian M, Haddon CO, Rose S, Jenner P (2005) The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci 22:317–330CrossRef Iravani MM, Leung CCM, Sadeghian M, Haddon CO, Rose S, Jenner P (2005) The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci 22:317–330CrossRef
go back to reference Kessler KR, Wunderlich G, Hefter H, Seitz RJ (2003) Secondary progressive chronic manganism associated with markedly decreased striatal D2 receptor density. Mov Disord 18(2):217–218CrossRef Kessler KR, Wunderlich G, Hefter H, Seitz RJ (2003) Secondary progressive chronic manganism associated with markedly decreased striatal D2 receptor density. Mov Disord 18(2):217–218CrossRef
go back to reference Klinker F, Hasan K, Paulus W, Nitsche MA, Liebetanz D (2013) Pharmacological blockade and genetic absence of the dopamine D2 receptor specifically modulate voluntary locomotor activity in mice. Behav Brain Res 242:117–124CrossRef Klinker F, Hasan K, Paulus W, Nitsche MA, Liebetanz D (2013) Pharmacological blockade and genetic absence of the dopamine D2 receptor specifically modulate voluntary locomotor activity in mice. Behav Brain Res 242:117–124CrossRef
go back to reference Kornhuber J, Brücke T, Angelberger P, Asenbaum S, Podreka I (1995) SPECT imaging of dopamine receptors with [123I]epidepride: characterization of uptake in the human brain. J Neural Transm Gen Sect 101(1.3):95–103CrossRef Kornhuber J, Brücke T, Angelberger P, Asenbaum S, Podreka I (1995) SPECT imaging of dopamine receptors with [123I]epidepride: characterization of uptake in the human brain. J Neural Transm Gen Sect 101(1.3):95–103CrossRef
go back to reference Lucchini RG, Martin CJ, Doney BC (2009) From manganism to manganese-induced Parkinsonism: a conceptual model based on the evolution of exposure. Neuromol Med 11:311–321CrossRef Lucchini RG, Martin CJ, Doney BC (2009) From manganism to manganese-induced Parkinsonism: a conceptual model based on the evolution of exposure. Neuromol Med 11:311–321CrossRef
go back to reference Martinez-Clemente J, Lopez-Arnau R, Carbo M, Pubill D, Camarasa J, Escubedo E (2013) Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. Psychopharmacology 229:295–306CrossRef Martinez-Clemente J, Lopez-Arnau R, Carbo M, Pubill D, Camarasa J, Escubedo E (2013) Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. Psychopharmacology 229:295–306CrossRef
go back to reference Roth JA, Zhenzheng L, Khoshbouei H (2013) The effect of manganese on dopamine toxicity and dopamine transporter (DAT) in control and DAT transfected HEK cells. Neurotoxicology 35:121–128CrossRef Roth JA, Zhenzheng L, Khoshbouei H (2013) The effect of manganese on dopamine toxicity and dopamine transporter (DAT) in control and DAT transfected HEK cells. Neurotoxicology 35:121–128CrossRef
go back to reference Sikk K, Taba P (2015) Methcathinon, “kitchen chemistry” and permanent neurological damage. Int Rev Neurobiol 120:257–271CrossRef Sikk K, Taba P (2015) Methcathinon, “kitchen chemistry” and permanent neurological damage. Int Rev Neurobiol 120:257–271CrossRef
go back to reference Sikk K, Taba P, Haldre S, Bergquist J, Nyholm D, Zjablov G, Asser T, Aquilonius SM (2007) Irreversible motor impairment in young addicts—ephedrone, manganism or both? Acta Neurol Scand 115:385–389CrossRef Sikk K, Taba P, Haldre S, Bergquist J, Nyholm D, Zjablov G, Asser T, Aquilonius SM (2007) Irreversible motor impairment in young addicts—ephedrone, manganism or both? Acta Neurol Scand 115:385–389CrossRef
go back to reference Sikk K, Taba P, Haldre S, Bergquist J, Nyholm D, Askmark H, Danfors T, Sörensen J, Thurfjell L, Raininko R, Eriksson R, Flink R, Färnstrand C, Aquilonius SM (2010) Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure. Acta Neurol Scand 121:237–243CrossRef Sikk K, Taba P, Haldre S, Bergquist J, Nyholm D, Askmark H, Danfors T, Sörensen J, Thurfjell L, Raininko R, Eriksson R, Flink R, Färnstrand C, Aquilonius SM (2010) Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure. Acta Neurol Scand 121:237–243CrossRef
go back to reference Sikk K, Haldre S, Aquilonius SM, Taba P (2011) Manganese-induced Parkinsonism due to ephedrone abuse. Parkinson’s Disease 2011:865319PubMedPubMedCentral Sikk K, Haldre S, Aquilonius SM, Taba P (2011) Manganese-induced Parkinsonism due to ephedrone abuse. Parkinson’s Disease 2011:865319PubMedPubMedCentral
go back to reference Sikk K, Haldre S, Aquilonius SM, Asser A, Paris M, Roose Ä, Petterson J, Eriksson SL, Bergquist J, Taba P (2013) Manganese-induced Parkinsonism in methcathinone abusers: bio-markers of exposure and follow-up. Eur J Neurol 20:915–920CrossRef Sikk K, Haldre S, Aquilonius SM, Asser A, Paris M, Roose Ä, Petterson J, Eriksson SL, Bergquist J, Taba P (2013) Manganese-induced Parkinsonism in methcathinone abusers: bio-markers of exposure and follow-up. Eur J Neurol 20:915–920CrossRef
go back to reference Stanwood GD, Leitch DB, Savchenko V, Wu J, Fitsanakis VA, Anderson DJ, Stankowski JN, Aschner M, McLaughlin B (2009) Manganese exposure is cytotoxic and alters dopaminergic and GABAergic neurons within the basal ganglia. J Neurochem 110:378–389CrossRef Stanwood GD, Leitch DB, Savchenko V, Wu J, Fitsanakis VA, Anderson DJ, Stankowski JN, Aschner M, McLaughlin B (2009) Manganese exposure is cytotoxic and alters dopaminergic and GABAergic neurons within the basal ganglia. J Neurochem 110:378–389CrossRef
go back to reference Stepens A, Groma V, Skuja S, Platkajis A, Aldiņš P, Ekateina I, Martinsone I, Bricis R, Donaghy M (2014) The outcome of the movement disorder in methcathinone abusers: clinical, MRI and manganesemia changes, and neuropathology. Eur J Neurol 21:199–205CrossRef Stepens A, Groma V, Skuja S, Platkajis A, Aldiņš P, Ekateina I, Martinsone I, Bricis R, Donaghy M (2014) The outcome of the movement disorder in methcathinone abusers: clinical, MRI and manganesemia changes, and neuropathology. Eur J Neurol 21:199–205CrossRef
go back to reference Tibbo P, Silverstone PH, McEwan AJB, Scott J, Joshua A, Golberg K (1997) A single photon emission computed tomography study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls. J Psychiatry Neurosci 22:39–45PubMedPubMedCentral Tibbo P, Silverstone PH, McEwan AJB, Scott J, Joshua A, Golberg K (1997) A single photon emission computed tomography study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls. J Psychiatry Neurosci 22:39–45PubMedPubMedCentral
Metadata
Title
Subacute administration of both methcathinone and manganese causes basal ganglia damage in mice resembling that in methcathinone abusers
Authors
Andres Asser
Atsuko Hikima
Mari Raki
Kim Bergström
Sarah Rose
Julius Juurmaa
Villem Krispin
Mari Muldmaa
Stella Lilles
Hanna Rätsep
Peter Jenner
Sulev Kõks
Pekka T. Männistö
Pille Taba
Publication date
01-05-2020
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 5/2020
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-019-02110-z

Other articles of this Issue 5/2020

Journal of Neural Transmission 5/2020 Go to the issue